• Skip to primary navigation
  • Skip to main content
  • Skip to footer
  • Pessoal
    • Webmail
    • Área de Docentes
    • Área de Não-Docentes
  • Estudantes
    • Webmail
    • Moodle
    • NetP@
    • Biblioteca
    • Escola Doutoral
    • Serviços Académicos
    • Trabalhar no IHMT

IHMT

Instituto de Higiene e Medicina Tropical

  • O Instituto
    • Missão
    • História
    • Mensagem do Diretor
    • Órgãos de governo
    • Docentes e investigadores
    • Unidades de Ensino e de Investigação
  • Ensino
    • Doutoramentos
    • Mestrados
    • Cursos de Especialização
    • Formação transversal
    • Cursos de Curta Duração
    • Ensino à Distância
    • Apoio ao Desenvolvimento
    • Serviços académicos
  • Investigação
    • Centro GHTM
    • Unidade de Clínica Tropical
    • Unidade de Microbiologia Médica
    • Unidade de Parasitologia Médica
    • Unidade de Saúde Pública Global
    • Serviço de Interesse Comum
    • Biobanco
    • Centro Colaborador da OMS
    • Publicações
  • Serviços e gestão
    • Biblioteca
    • Sistema de Qualidade
    • Estatutos e regulamentos
    • Relatórios
    • Contratos públicos
    • Recursos humanos
      • Concursos e bolsas
      • Contratos
      • Avaliação e Desempenho
        • Processo Eleitoral da Comissão Paritária
      • Mobilidade
  • Doenças Tropicais
    • Consulta do Viajante
    • Glossário
    • Museu
    • Vídeos
    • MosquitoWeb
  • Comunidade
    • Cooperação e Desenvolvimento
    • Formação
    • Parcerias
  • Contactos
  • Português
  • English
Home / Archives for Vercauteren J

Vercauteren J

Gender differences in HIV disease progression and treatment outcomes among HIV patients one year after starting antiretroviral treatment (ART) in Dar es Salaam, Tanzania

  • Autores: Lyamuya E, Matee M, Mosha F, Muchunguzi V, Nsubuga P, Sangeda RZ, Vandamme AM, Vercauteren J
  • Ano de Publicação: 2013
  • Journal: BMC Public Health
  • Link: http://www.biomedcentral.com/1471-2458/13/38

We investigated gender differences in treatment outcome during first line antiretroviral treatment (ART) in a hospital setting in Tanzania, assessing clinical, social demographic, virological and immunological factors.
Ler mais

HIV-1 fitness landscape models for indinavir treatment pressure using observed evolution in longitudinal sequence data are predictive for treatment failure

  • Autores: Beheydt G, Bruzzone B, Camacho RJ, De Luca A, Deforche K, Grossman Z, Imbrechts S, Incardona F, Libin P, Pironti A, Rhee SY, Ruiz L, Sangeda RZ, Shafer RW, Sönnerborg A, Theys K, Torti C, Van de Vijver DA, Van Laethem K, Van Wijngaerden E, Vandamme AM, Vercauteren J, Zazzi M
  • Ano de Publicação: 2013
  • Journal: Infection Genetics and Evolution
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/23523594

We previously modeled the in vivo evolution of human immunodeficiency virus-1 (HIV-1) under drug selective pressure from cross-sectional viral sequences. These fitness landscapes (FLs) were made by using first a Bayesian network (BN) to map epistatic substitutions, followed by scaling the fitness landscape based on an HIV evolution simulator trying to evolve the sequences from treatment naïve patients into sequences from patients failing treatment.
Ler mais

Expected HIV-1 etravirine resistance after treatment failure with efavirenz and/or nevirapine

  • Autores: Beheydt G, Camacho R, Carvalho AP, Grossman Z, Levy I, Ram D, Rudich H, Van Laethem K, Vandamme AM, Vercauteren J
  • Ano de Publicação: 2010
  • Journal: Antiviral Therapy
  • Link: https://apps.webofknowledge.com/full_record.do?product=UA&search_mode=GeneralSearch&qid=2&SID=Z1yZbyGlNxI3xGo9eDj&page=1&doc=1

Ler mais

Cellular HIV-1 DNA levels in drug sensitive strains are equivalent to those in drug resistant strains in newly-diagnosed patients in Europe

  • Autores: Balotta C, Clotet B, Demetriou VL, Grossman Z, Jørgensen LB, Kostrikis LG, Kousiappa I, Lepej SZ, Levy I, Nielsen C, Paraskevis D, Poljak M, Roman F, Ruiz L, Schmidt JC, Van de Vijver DA, Van Laethem K, Vandamme AM, Vercauteren J
  • Ano de Publicação: 2010
  • Journal: PLoS One
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/20544014

BACKGROUND:
HIV-1 genotypic drug resistance is an important threat to the success of antiretroviral therapy and transmitted resistance has reached 9% prevalence in Europe. Studies have demonstrated that HIV-1 DNA load in peripheral blood mononuclear cells (PBMC) have a predictive value for disease progression, independently of CD4 counts and plasma viral load.
Ler mais

Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients.

  • Autores: Albert J, Åsjö B, Balotta C, Boucher CA, Bruckova M, Camacho RJ, Clotet B, Coughlan S, Deforche K, Grossman Z, Hamouda O, Horban A, Korn K, Kostrikis LG, Kücherer C, Libin P, Liitsola K, Nielsen C, Paraskevis D, Poljak M, Puchhammer-Stöckl E, Riva C, Ruiz L, Schmit JC, Schuurman R, Sönnerborg A, SPREAD-programme, Staneková D, Stanojevic M, Struck D, Theys K, Van de Vijver DA, Van Laethem K, Vandamme AM, Vercauteren J, Wensing AM
  • Ano de Publicação: 2012
  • Journal: Retrovirology
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=Treatment-associated+polymorphisms+in+protease+are+significantly+associated+with+higher+viral+load+and+lower+CD4+count+in+newly+diagnosed+drug-naive+HIV-1+infected+patients

BACKGROUND:
The effect of drug resistance transmission on disease progression in the newly infected patient is not well understood. Major drug resistance mutations severely impair viral fitness in a drug free environment, and therefore are expected to revert quickly. Compensatory mutations, often already polymorphic in wild-type viruses, do not tend to revert after transmission.
Ler mais

HIV-1 transmitted drug resistance in Latin America and the Caribbean: what do we know?

  • Autores: Bello DC, Gomez-Lopez A, Pineda-Peña AC, Sussmann O, Van Laethem K, Vandamme AM, Vercauteren J
  • Ano de Publicação: 2012
  • Journal: Aids Reviews
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=HIV-1+Transmitted+Drug+Resistance+in+Latin+America+and+the+Caribbean%3A+What+Do+We+Know%3F

Latin America and the Caribbean countries have increased the scaling-up of antiretroviral treatment in the last years. The increase of transmitted drug resistance has been feared due to the worrisome indicators associated with the emergence of drug resistance and monitored by the World Health Organization (WHO).
Ler mais

The demise of multidrug- resistant HIV-1: The national time trend in Portugal

  • Autores: Aguas MJ, Camacho RJ, Carvalho AP, Duque LM, Faria D, Faria T, Mansinho K, Peres S, Teófilo E, Theys K, Valadas E, Vandamme AM, Vera J, Vercauteren J
  • Ano de Publicação: 2013
  • Journal: Journal of Antimicrobial Chemotherapy
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/23228933

Despite a decreasing mortality and morbidity in treated HIV-1 patients, highly active antiretroviral treatment (HAART) can still fail due to the development of drug resistance. Especially, multidrug-resistant viruses pose a threat to efficient therapy. We studied the changing prevalence of multidrug resistance (MDR) over time in a cohort of HIV-1-infected patients in Portugal.
Ler mais

Clinical Evaluation of Rega 8: An Updated Genotypic Interpretation System That Significantly Predicts HIV-Therapy Response

  • Autores: Beheydt G, Camacho R, Clotet B, De Luca A, Geretti AM, Grossman Z, Imbrechts S, Kaiser R, Libin P, Prosperi M, Schmit JC, Sönnerborg A, Torti C, Van Laethem K, Van Wijngaerden E, Vandamme AM, Vercauteren J, Zazzi M
  • Ano de Publicação: 2013
  • Journal: PLoS One
  • Link: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0061436

Clinically evaluating genotypic interpretation systems is essential to provide optimal guidance in designing potent individualized HIV-regimens. This study aimed at investigating the ability of the latest Rega algorithm to predict virological response on a short and longer period.
Ler mais

HIV-1 subtype is an independent predictor of reverse transcriptase mutation k65r in HIV-1 patients treated with combination antiretroviral therapy including tenofovir

  • Autores: Abecasis AB, Camacho RJ, Clotet B, De Luca A, Grossman Z, Schülter E, Snoeck J, Sönnerborg A, Struck D, Theys K, Torti C, Vandamme AM, Vercauteren J, Zazzi M
  • Ano de Publicação: 2013
  • Journal: Antimicrobial Agents and Chemotherapy
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/23183438

Subtype-dependent selection of HIV-1 reverse transcriptase resistance mutation K65R was previously observed in cell culture and small clinical investigations. We compared K65R prevalence across subtypes A, B, C, F, G, and CRF02_AG separately in a cohort of 3,076 patients on combination therapy including tenofovir. K65R selection was significantly higher in HIV-1 subtype C. This could not be explained by clinical and demographic factors in multivariate analysis, suggesting subtype sequence-specific K65R pathways.
Ler mais

Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving com- bination therapy including tenofovir

  • Autores: Abecasis AB, Abreu R, Aguas MJ, Aldir I, Aleixo MJ, Amaro G, Antunes F, Borges F, Botas J, Branco T, Caixas U, Camacho RJ, Diniz A, Doroana M, Duque L, Faria D, Faria N, Faria T, Fonseca P, Germano I, Gomes F, Guerreiro C, Jesus MB, Mansinho K, Mineiro A, Miranda AC, Narciso J, Neves I, Nina J, Pinheiro S, Pinto IV, Proença P, Reis AP, Roxo F, Sá J, Santos C, Snoeck J, Tavares L, Teófilo E, Theys K, Valadas E, Vandamme AM, Ventura F, Vera J, Vercauteren J
  • Ano de Publicação: 2013
  • Journal: Journal of Antimicrobial Chemotherapy
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/23027713

The use of tenofovir is highly associated with the emergence of mutation K65R, which confers broad resistance to nucleoside/nucleotide analogue reverse transcriptase inhibitors (NRTIs), especially when tenofovir is combined with other NRTIs also selecting for K65R. Although recent HIV-1 treatment guidelines discouraging these combinations resulted in reduced K65R selection with tenofovir, updated information on the impact of currently recommended regimens on the population selection rate of K65R is presently lacking.
Ler mais

  • Go to page 1
  • Go to page 2
  • Go to Next Page »

Footer

INSTITUTO DE HIGIENE E
MEDICINA TROPICAL
UNIVERSIDADE NOVA DE LISBOA
Rua da Junqueira, 100 1349-008 Lisboa
T +351 213 652 600
geral@ihmt.unl.pt

Consulta do Viajante e Medicina Tropical
T +351 213 652 630
T +351 213 652 690
T +351 91 182 37 48
T +351 91 182 44 67
medicina.viagens@ihmt.unl.pt

Ensino
Investigação
Medicina Tropical
Cooperação

Siga-nos

  • Facebook
  • LinkedIn
  • YouTube

Receber a “newsletter”

© Copyright 2023 IHMT-UNL Todos os Direitos Reservados.
  • Universidade Nova de Lisboa
  • Fundação para a Ciência e a Tecnologia

    Project UID/Multi/04413/2013